Phase 3 Schizophrenia Trial, Recruiting NCT07424404 Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company Condition: Schizophrenia
Back to Schizophrenia

Phase 3 Schizophrenia Trial, Recruiting

NCT07424404
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have completed the full treatment period of one of three related studies (CN0120020, CN0120044, or CN0120045) without experiencing a side effect that the study doctor considered a serious safety concern.

Who may not be able to join:

  • People who have a history of, or show signs of, being at significant risk of harming others, seriously harming themselves, or attempting suicide — including those who answered "Yes" to certain specific questions about suicidal thoughts on a standard safety questionnaire at the first visit (note: non-suicidal self-harm on its own does not automatically disqualify you — confirm with trial site).
  • People who have any significant abnormal results from a physical check-up, measurements like heart rate or temperature, or a heart tracing (ECG) taken at the end of one of the related studies, if the study doctor believes these results could put the participant at risk.
  • People whose blood pressure reading — either the top number (systolic) or the bottom number (diastolic) — is high enough to be classified as "stage 2 high blood pressure," regardless of whether they have symptoms.
  • There may be additional requirements not listed here that could affect eligibility (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Australian sites

Local Institution - 0107, Westmead, New South Wales
Local Institution - 0106, Brisbane, Queensland
Local Institution - 0108, Melbourne, Victoria
Local Institution - 0109, Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Registry
ClinicalTrials.gov
Start date
7 April 2026
Est. completion
8 March 2030

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇨🇦 Canada 🇫🇷 France 🇩🇪 Germany 🇭🇺 Hungary 🇯🇵 Japan 🇵🇱 Poland 🇷🇴 Romania 🇪🇸 Spain 🇺🇸 United States

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of participants with treatment emergent adverse events (TEAEs); Number of participants with adverse events of special interest (AESIs); Number of participants with serious adverse events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov